MD MEDICAL GROUP INVESTMENTS PLC financials
MD MEDICAL GROUP INVESTMENTS PLC
213800XKI6VHY4JBS612 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | RUB 25.22B | RUB 25.22B |
| Cost of sales | RUB 15.43B | RUB 15.23B |
| Gross profit | RUB 9.79B | RUB 9.99B |
| Other income | RUB 36.1M | RUB 104.4M |
| Operating profit (EBIT) | RUB 4.97B | RUB 6.62B |
| Net finance income / (cost) | -RUB 243.0M | -RUB 463.7M |
| Finance costs | RUB 494.0M | RUB 549.4M |
| Profit before tax | RUB 4.73B | RUB 6.16B |
| Income tax expense | RUB 7.6M | RUB 15.2M |
| Profit for the year | RUB 4.72B | RUB 6.14B |
| — attributable to owners | RUB 4.56B | RUB 6.00B |
| — attributable to NCI | RUB 158.6M | RUB 139.5M |
| Total comprehensive income | RUB 4.72B | RUB 6.14B |
| Cash flow statement | ||
| Cash generated from operations | RUB 7.75B | RUB 8.50B |
| Net cash from operating activities | RUB 7.73B | RUB 8.50B |
| Net cash from investing activities | -RUB 848.4M | -RUB 2.91B |
| Purchase of PP&E (capex) | RUB 1.10B | RUB 3.73B |
| Purchase of intangibles | RUB 70.0M | RUB 55.5M |
| Net cash from financing activities | -RUB 5.90B | -RUB 5.03B |
| Dividends paid | RUB 852.7M | RUB 3.00B |
| Repayments of borrowings | RUB 4.81B | RUB 1.49B |
| Lease liability payments | RUB 150.7M | RUB 152.5M |
| Net change in cash | RUB 981.3M | RUB 556.5M |
| Balance sheet | ||
| Total assets | RUB 33.16B | RUB 34.28B |
| Non-current assets | RUB 26.58B | RUB 28.56B |
| Property, plant & equipment | RUB 24.53B | RUB 26.07B |
| Intangible assets & goodwill | RUB 1.96B | RUB 2.14B |
| Current assets | RUB 6.59B | RUB 5.73B |
| Inventories | RUB 1.21B | RUB 1.16B |
| Cash & equivalents | RUB 4.46B | RUB 3.59B |
| Total equity | RUB 26.96B | RUB 23.10B |
| — attributable to owners | RUB 26.75B | RUB 22.83B |
| Non-controlling interests | RUB 212.7M | RUB 264.5M |
| Non-current liabilities | RUB 1.69B | RUB 4.82B |
| Long-term borrowings | RUB 489.2M | RUB 3.73B |
| Current liabilities | RUB 4.51B | RUB 6.37B |
| Short-term borrowings | RUB 106.4M | RUB 1.79B |
| Trade & other payables | RUB 2.82B | RUB 3.01B |
| Deferred tax liabilities | RUB 0 | RUB 6.2M |
| Derived metrics | ||
| Free cash flow | RUB 6.63B | RUB 4.76B |
| Operating margin | 19.7% | 26.3% |
| Net margin | 18.7% | 24.4% |
| Return on equity | 17.5% | 26.6% |
| Cash conversion ratio | 1.64× | 1.38× |
| Capex coverage | 7.04× | 2.28× |
| Other reported items | ||
| Adjustments For Amortisation Expense | RUB 51.1M | RUB 122.2M |
| Adjustments For Decrease Increase In Inventories | -RUB 47.4M | -RUB 190.9M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -RUB 35.3M | -RUB 7.9M |
| Adjustments For Depreciation Expense | RUB 1.62B | RUB 1.58B |
| Adjustments For Finance Costs | RUB 400.2M | RUB 517.7M |
| Adjustments For Finance Income | RUB 355.8M | RUB 93.7M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | RUB 1.29B | RUB 0 |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade and Other Receivables | RUB 93.8M | RUB 31.6M |
| Adjustments For Income Tax Expense | RUB 7.6M | RUB 15.2M |
| Adjustments For Increase Decrease In Contract Liabilities | -RUB 17.6M | RUB 80.3M |
| Adjustments For Increase Decrease In Trade and Other Payables | -RUB 55.4M | RUB 276.3M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | RUB 104.8M | RUB 8.0M |
| Cash Flows From Used In Operations Before Changes In Working Capital | RUB 7.90B | RUB 8.35B |
| Comprehensive Income Attributable To Noncontrolling Interests | RUB 158.6M | RUB 139.5M |
| Comprehensive Income Attributable To Owners of Parent | RUB 4.56B | RUB 6.00B |
| Current Contract Liabilities | RUB 1.58B | RUB 1.57B |
| Deferred Tax Assets | RUB 0 | RUB 4.3M |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | RUB 636.8M | RUB 2.73B |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | RUB 224.8M | RUB 178.2M |
| Dividends Recognised As Distributions To Owners Per Share | RUB 18000.00 | RUB 19000.00 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | RUB 108.2M | RUB 95.6M |
| Equity and Liabilities | RUB 33.16B | RUB 34.28B |
| Finance Income | RUB 355.8M | RUB 93.7M |
| Gains Losses On Exchange Differences On Translation Before Tax | -RUB 104.8M | -RUB 8.0M |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | RUB 1.29B | RUB 0 |
| Income Taxes Paid Refund Classified As Operating Activities | RUB 12.6M | RUB 4.6M |
| Increase Decrease Through Transfers and Other Changes Equity | — | RUB 431.0K |
| Interest Paid Classified As Financing Activities | RUB 262.1M | RUB 363.7M |
| Interest Received Classified As Investing Activities | RUB 257.8M | RUB 93.7M |
| Issued Capital | RUB 180.6M | RUB 180.6M |
| Liabilities | RUB 6.20B | RUB 11.19B |
| Noncurrent Contract Liabilities | RUB 468.5M | RUB 460.4M |
| Noncurrent Payables | RUB 729.2M | RUB 624.8M |
| Other Expense By Function | RUB 60.5M | RUB 68.0M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | RUB 62.8M | RUB 2.7M |
| Retained Earnings | RUB 21.98B | RUB 18.06B |
| Selling General and Administrative Expense | RUB 3.51B | RUB 3.40B |
| Share Premium | RUB 5.24B | RUB 5.24B |
| Trade and Other Receivables | RUB 911.8M | RUB 971.3M |
Every line item above is a fact tagged in MD MEDICAL GROUP INVESTMENTS PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (RUB), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.